<p>不列颠哥伦比亚省温哥华 --（Newsfile Corp. -2026 年 5 月 7 日）- Restart Life Sciences Corp.（CSE: HEAL）（FSE: HN30）（OTC Pink: NMLSF）（&#34;Restart Life&#34;或&#34;公司&#34;）很高兴地宣布 Lindsay Hamelin 被任命为公司独立董事，立即生效。</p>
<p>Hamelin 女士拥有超过 20 年的资本市场和企业融资经验，特别擅长企业结构、并购和公共公司环境中的融资策略。在她的职业生涯中，她支持并咨询公共发行人处理复杂交易、资本筹集和旨在支持增长和提升股东价值的战略企业发展计划。</p>
<p>她的丰富经验包括结构化和执行各种融资交易，包括股权发行和战略资本计划，以及在企业重组和并购活动方面提供咨询。Hamelin 女士与管理团队密切合作，使企业结构与长期战略目标和资本市场执行保持一致。</p>
<p>&#34;我们非常高兴欢迎 Lindsay 加入董事会，&#34;Restart Life 的首席执行官 Steve Loutskou 说。&#34;她在资本市场和并购方面的 20 年经验为我们下一阶段的战略增长提供了所需的高层监督。随着我们继续评估战略机会并在'更健康'的功能性食品和消费品市场中扩展，她的视角将极具价值。&#34;</p>
<p>Hamelin 女士的任命进一步加强了 Restart Life 的董事会，因为公司继续推进其增长战略，专注于严格的资本配置、企业发展以及在其品牌和知识产权组合中的扩展。</p>
<p>Restart Life Sciences 感谢其股东的持续支持，因为公司推进其使命并继续执行其战略。</p>
<p><strong>关于 Restart Life Sciences Corp.</strong></p>
<p>Restart Life Sciences Corp.是一家总部位于加拿大的生命科学公司，上市于 CSE。有关 Restart Life 的更多信息，请访问公司网站 www.restartlife.co。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含构成&#34;前瞻性声明&#34;的陈述。这些前瞻性声明涉及已知和未知的风险、不确定性及其他因素，可能导致 Restart 的实际结果、表现或成就，或行业发展与预期结果、表现或成就存在重大差异。前瞻性声明是指非历史事实的陈述，通常但不总是通过&#34;预计&#34;、&#34;计划&#34;、&#34;预期&#34;、&#34;相信&#34;、&#34;打算&#34;、&#34;估计&#34;、&#34;项目&#34;、&#34;潜在&#34;及类似表达来识别，或事件或条件&#34;将&#34;、&#34;会&#34;、&#34;可能&#34;、&#34;能够&#34;或&#34;应该&#34;发生。此信息和这些陈述在此称为&#34;前瞻性声明&#34;，并非历史事实，均以本新闻稿日期为准，包括但不限于与收购的完成及相关先决条件的满足或豁免及其时机、收购的预期利益、Restart 将 Holy Crap 的业务整合到其现有运营中的能力；垂直整合合作包装设施的好处；预期的关闭日期，以及公司对 Holy Crap 的期望。</p>
<p>这些前瞻性声明涉及众多风险和不确定性，实际结果可能与任何前瞻性声明中建议的结果存在重大差异。这些风险和不确定性包括但不限于：与收购相关的固有风险和不确定性、公司的财务状况、预期收购的好处可能未能完全实现或实现所需时间比预期更长；市场波动；公司证券的金融市场状况；以及一般商业、经济、竞争、政治和社会不确定性。在本新闻稿中做出前瞻性声明时，公司已应用若干重要假设，包括但不限于，满足或豁免《最终协议》中所有关闭条件，Restart 将能够成功将 Holy Crap 资产整合到其现有运营中；以及当前和未来的社会、经济和政治条件。</p>
<p>尽管公司的管理层已尝试识别可能导致实际结果与前瞻性声明或前瞻性信息中包含的结果存在重大差异的重要因素，但可能还有其他因素导致结果未如预期、估计或意图。不能保证这些声明将被证明是准确的，因为实际结果和未来事件可能与这些声明中表达或暗示的结果存在重大差异。因此，读者不应对前瞻性声明和前瞻性信息过度依赖。读者被提醒，依赖这些信息可能不适合其他目的。公司不承担更新任何前瞻性声明、前瞻性信息或财务展望的责任，除非根据适用的证券法。鼓励读者查阅公司在某些加拿大省份向证券监管机构提交的持续披露文件，并可在 www.sedarplus.ca 获取。</p>
<p>加拿大证券交易所及其市场监管机构（根据加拿大证券交易所政策定义的术语）对本公告的充分性或准确性不承担责任。</p>
<p><strong>代表董事会</strong></p>
<p>Steve Loutskou</p>
<p>首席执行官，Restart Life Sciences Corp.</p>
<p>电话：+1 (778) 819-0244</p>
<p>电子邮件：hello@restartlife.co</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/8801/296414_81085b4ad41f4a9e_logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/8801/296414_81085b4ad41f4a9e_logo.jpg"/></p>
<p>要查看本新闻稿的源版本，请访问 https://www.newsfilecorp.com/release/296414</p>
<p><img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/296414/375?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/296414/375"/></p>

RSLS

ATNF

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 3 倍做多 - Direxion

生物科技 ETF - VanEck Vectors

<p>Restart Life Sciences Corp. 已任命 Lindsay Hamelin 为独立董事，立即生效。她在资本市场和企业融资方面拥有超过 20 年的经验，将为公司的战略增长提供监督。首席执行官 Steve Loutskou 对她提升股东价值和支持公司在功能性食品和消费品市场扩展的能力表示信心。此次任命旨在加强董事会，因为 Restart Life 继续其增长战略和严格的资本配置</p>

<p>Vancouver, British Columbia--(Newsfile Corp. - May 7, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) (&#34;Restart Life&#34; or the &#34;Company&#34;) is pleased to announce the appointment of Lindsay Hamelin as an Independent Director of the Company, effective immediately.</p>
<div class="lb-trans"><p>不列颠哥伦比亚省温哥华 --（Newsfile Corp. -2026 年 5 月 7 日）- Restart Life Sciences Corp.（CSE: HEAL）（FSE: HN30）（OTC Pink: NMLSF）（&#34;Restart Life&#34;或&#34;公司&#34;）很高兴地宣布 Lindsay Hamelin 被任命为公司独立董事，立即生效。</p>
</div><p>Ms. Hamelin brings over 20 years of capital markets and corporate finance experience, with a specific expertise in corporate structuring, mergers and acquisitions, and financing strategies within public company environments. Throughout her career, she has supported and advised public issuers on complex transactions, capital raises, and strategic corporate development initiatives designed to support growth and enhance shareholder value.</p>
<div class="lb-trans"><p>Hamelin 女士拥有超过 20 年的资本市场和企业融资经验，特别擅长企业结构、并购和公共公司环境中的融资策略。在她的职业生涯中，她支持并咨询公共发行人处理复杂交易、资本筹集和旨在支持增长和提升股东价值的战略企业发展计划。</p>
</div><p>Her extensive experience includes structuring and executing a wide range of financing transactions, including equity offerings and strategic capital initiatives, as well as advising on corporate reorganizations and M&amp;A activity. Ms. Hamelin has worked closely with management teams on aligning corporate structures with long-term strategic objectives and capital markets execution.</p>
<div class="lb-trans"><p>她的丰富经验包括结构化和执行各种融资交易，包括股权发行和战略资本计划，以及在企业重组和并购活动方面提供咨询。Hamelin 女士与管理团队密切合作，使企业结构与长期战略目标和资本市场执行保持一致。</p>
</div><p>&#34;We are very pleased to welcome Lindsay to the Board,&#34; said Steve Loutskou, CEO of Restart Life. &#34;Her 20-year track record in capital markets and M&amp;A provides us with the high-level oversight needed for our next phase of strategic growth. Her perspective will be highly valuable as we continue to evaluate strategic opportunities and execute on our expansion within the 'better-for-you' functional food and CPG markets.&#34;</p>
<div class="lb-trans"><p>&#34;我们非常高兴欢迎 Lindsay 加入董事会，&#34;Restart Life 的首席执行官 Steve Loutskou 说。&#34;她在资本市场和并购方面的 20 年经验为我们下一阶段的战略增长提供了所需的高层监督。随着我们继续评估战略机会并在'更健康'的功能性食品和消费品市场中扩展，她的视角将极具价值。&#34;</p>
</div><p>Ms. Hamelin's appointment further strengthens Restart Life's Board as the Company continues to advance its growth strategy, with a focus on disciplined capital allocation, corporate development, and expansion within its portfolio of brands and intellectual property.</p>
<div class="lb-trans"><p>Hamelin 女士的任命进一步加强了 Restart Life 的董事会，因为公司继续推进其增长战略，专注于严格的资本配置、企业发展以及在其品牌和知识产权组合中的扩展。</p>
</div><p>Restart Life Sciences would like to thank its shareholders for their ongoing support as the Company advances its mission and continues to execute on its strategy.</p>
<div class="lb-trans"><p>Restart Life Sciences 感谢其股东的持续支持，因为公司推进其使命并继续执行其战略。</p>
</div><p><strong>About Restart Life Sciences Corp.</strong></p>
<div class="lb-trans"><p><strong>关于 Restart Life Sciences Corp.</strong></p>
</div><p>Restart Life Sciences Corp. is a Canadian-based life sciences company listed on the CSE. For more information about Restart Life, please visit the Company's website at www.restartlife.co.</p>
<div class="lb-trans"><p>Restart Life Sciences Corp.是一家总部位于加拿大的生命科学公司，上市于 CSE。有关 Restart Life 的更多信息，请访问公司网站 www.restartlife.co。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This news release contains statements that constitute &#34;forward-looking statements.&#34; Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Restart's actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words &#34;expects,&#34; &#34;plans,&#34; &#34;anticipates,&#34; &#34;believes,&#34; &#34;intends,&#34; &#34;estimates,&#34; &#34;projects,&#34; &#34;potential&#34; and similar expressions, or that events or conditions &#34;will,&#34; &#34;would,&#34; &#34;may,&#34; &#34;could&#34; or &#34;should&#34; occur. This information and these statements, referred to herein as &#34;forward-looking statements&#34;, are not historical facts, are made as of the date of this news release and include without limitation, statements relating to the closing of the Acquisition and the satisfaction or waiver of the related conditions precedent and the timing thereof, the perceived benefits of the Acquisition, the ability for Restart to integrate Holy Crap's business into its existing operations; the benefits of vertically integrating the co-packer facility; anticipated closing date, and the Company's expectations relating to Holy Crap.</p>
<div class="lb-trans"><p>本新闻稿包含构成&#34;前瞻性声明&#34;的陈述。这些前瞻性声明涉及已知和未知的风险、不确定性及其他因素，可能导致 Restart 的实际结果、表现或成就，或行业发展与预期结果、表现或成就存在重大差异。前瞻性声明是指非历史事实的陈述，通常但不总是通过&#34;预计&#34;、&#34;计划&#34;、&#34;预期&#34;、&#34;相信&#34;、&#34;打算&#34;、&#34;估计&#34;、&#34;项目&#34;、&#34;潜在&#34;及类似表达来识别，或事件或条件&#34;将&#34;、&#34;会&#34;、&#34;可能&#34;、&#34;能够&#34;或&#34;应该&#34;发生。此信息和这些陈述在此称为&#34;前瞻性声明&#34;，并非历史事实，均以本新闻稿日期为准，包括但不限于与收购的完成及相关先决条件的满足或豁免及其时机、收购的预期利益、Restart 将 Holy Crap 的业务整合到其现有运营中的能力；垂直整合合作包装设施的好处；预期的关闭日期，以及公司对 Holy Crap 的期望。</p>
</div><p>These forward‐looking statements involve numerous risks and uncertainties and actual results might differ materially from results suggested in any forward-looking statements. These risks and uncertainties include, among other things: the inherent risks and uncertainties associated with the Acquisition, the Company's financial condition, the risk that the anticipated benefits of the Acquisition may not be fully realized or take longer to realize than expected; market volatility; the state of the financial markets for the Company's securities; and general business, economic, competitive, political and social uncertainties;. In making the forward-looking statements in this news release, the Company has applied several material assumptions, including without limitation, the satisfaction or waiver of all closing conditions in the Definitive Agreement, that Restart will be able to successfully integrate the Holy Crap assets into its existing operations; and the current and future social, economic and political conditions.</p>
<div class="lb-trans"><p>这些前瞻性声明涉及众多风险和不确定性，实际结果可能与任何前瞻性声明中建议的结果存在重大差异。这些风险和不确定性包括但不限于：与收购相关的固有风险和不确定性、公司的财务状况、预期收购的好处可能未能完全实现或实现所需时间比预期更长；市场波动；公司证券的金融市场状况；以及一般商业、经济、竞争、政治和社会不确定性。在本新闻稿中做出前瞻性声明时，公司已应用若干重要假设，包括但不限于，满足或豁免《最终协议》中所有关闭条件，Restart 将能够成功将 Holy Crap 资产整合到其现有运营中；以及当前和未来的社会、经济和政治条件。</p>
</div><p>Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those expressed or implied in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws. Readers are encouraged to read the Company's continuous disclosure documents filed with the securities regulatory authorities in certain provinces of Canada and available at www.sedarplus.ca.</p>
<div class="lb-trans"><p>尽管公司的管理层已尝试识别可能导致实际结果与前瞻性声明或前瞻性信息中包含的结果存在重大差异的重要因素，但可能还有其他因素导致结果未如预期、估计或意图。不能保证这些声明将被证明是准确的，因为实际结果和未来事件可能与这些声明中表达或暗示的结果存在重大差异。因此，读者不应对前瞻性声明和前瞻性信息过度依赖。读者被提醒，依赖这些信息可能不适合其他目的。公司不承担更新任何前瞻性声明、前瞻性信息或财务展望的责任，除非根据适用的证券法。鼓励读者查阅公司在某些加拿大省份向证券监管机构提交的持续披露文件，并可在 www.sedarplus.ca 获取。</p>
</div><p>Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.</p>
<div class="lb-trans"><p>加拿大证券交易所及其市场监管机构（根据加拿大证券交易所政策定义的术语）对本公告的充分性或准确性不承担责任。</p>
</div><p><strong>On behalf of the Board of Directors</strong></p>
<div class="lb-trans"><p><strong>代表董事会</strong></p>
</div><p>Steve Loutskou</p>
<div class="lb-trans"><p>Steve Loutskou</p>
</div><p>Chief Executive Officer, Restart Life Sciences Corp.</p>
<div class="lb-trans"><p>首席执行官，Restart Life Sciences Corp.</p>
</div><p>Tel: +1 (778) 819-0244</p>
<div class="lb-trans"><p>电话：+1 (778) 819-0244</p>
</div><p>Email: hello@restartlife.co</p>
<div class="lb-trans"><p>电子邮件：hello@restartlife.co</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/8801/296414_81085b4ad41f4a9e_logo.jpg" alt="" original-src="https://images.newsfilecorp.com/files/8801/296414_81085b4ad41f4a9e_logo.jpg"/></p>
<p>To view the source version of this press release, please visit https://www.newsfilecorp.com/release/296414</p>
<div class="lb-trans"><p>要查看本新闻稿的源版本，请访问 https://www.newsfilecorp.com/release/296414</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/296414/375" alt="" original-src="https://api.newsfilecorp.com/newsinfo/296414/375"/></p>

Restart Life Sciences 任命资本市场资深人士 Lindsay Hamelin 加入董事会 | NMLSF 股票新闻